Glycosylated proteins, namely glycoproteins and proteoglycans (collectively called glycoconjugates), are indispensable in a variety of biological processes. The functions of many glycoconjugates are regulated by their interactions with another group of proteins known as lectins. In order to understand the biological functions of lectins and their glycosylated binding partners, one must obtain these proteins in pure form. The conventional protein purification methods often require long times, elaborate infrastructure, costly reagents, and large sample volumes. To minimize some of these problems, we recently developed and validated a new method termed capture and release (CaRe). This method is time‐saving, precise, inexpensive, and it needs a relatively small sample volume. In this approach, targets (lectins and glycoproteins) are captured in solution by multivalent ligands called target capturing agents (TCAs). The captured targets are then released and separated from their TCAs to obtain purified targets. Application of the CaRe method could play an important role in discovering new lectins and glycoconjugates. © 2020 Wiley Periodicals LLC.
Class II major histocompatibility complex peptide (MHC‐IIp) multimers are precisely engineered reagents used to detect T cells specific for antigens from pathogens, tumors, and self‐proteins. While the related Class I MHC/peptide (MHC‐Ip) multimers are usually produced from subunits expressed in
This article was corrected on 19 July 2022. See the end of the full text for details.
- NSF-PAR ID:
- 10237684
- Publisher / Repository:
- Wiley Blackwell (John Wiley & Sons)
- Date Published:
- Journal Name:
- Current Protocols
- Volume:
- 1
- Issue:
- 2
- ISSN:
- 2691-1299
- Format(s):
- Medium: X
- Sponsoring Org:
- National Science Foundation
More Like this
-
more » « less
Abstract Basic Protocol 1 : Preparation of crude extracts containing the target proteins from soybean flourAlternate Protocol 1 : Preparation of crude extracts from Jack bean mealAlternate Protocol 2 : Preparation of crude extracts from the corms ofColocasia esculenta ,Xanthosoma sagittifolium , and from the bulbs ofAllium sativum Alternate Protocol 3 : Preparation ofEscherichia coli cell lysates containing human galectin‐3Alternate Protocol 4 : Preparation of crude extracts from chicken egg whites (source of ovalbumin)Basic Protocol 2 : Preparation of 2% (v/v) red blood cell suspensionBasic Protocol 3 : Detection of lectin activity of the crude extractsBasic Protocol 4 : Identification of multivalent inhibitors as target capturing agents by hemagglutination inhibition assaysBasic Protocol 5 : Testing the capturing abilities of target capturing agents by precipitation/turbidity assaysBasic Protocol 6 : Capturing of targets (lectins and glycoproteins) in the crude extracts by target capturing agents and separation of the target‐TCA complex from other components of the crude extractsBasic Protocol 7 : Releasing the captured targets (lectins and glycoproteins) by dissolving the complexBasic Protocol 8 : Separation of the targets (lectins and glycoproteins) from their respective target capturing agentsBasic Protocol 9 : Verification of the purity of the isolated targets (lectins or glycoproteins) -
more » « less
Abstract Protein S‐acylation, predominately in the form of palmitoylation, is a reversible lipid post‐translational modification on cysteines that plays important roles in protein localization, trafficking, activity, and complex assembly. The functions and regulatory mechanisms of S‐acylation have been extensively studied in mammals owing to remarkable development of high‐resolution proteomics and the discovery of the S‐acylation‐related enzymes. However, the advancement of S‐acylation studies in plants lags behind that in mammals, mainly due to the lack of knowledge about proteins responsible for this process, such as protein acyltransferases and their substrates. In this article, a set of systematic protocols to study global S‐acylation in
Arabidopsis seedlings is described. The procedures are presented in detail, including preparation ofArabidopsis seedlings, enrichment of plasma membrane (PM) proteins, ensuing enrichment of S‐acylated proteins/peptides based on the acyl‐biotin exchange method, and large‐scale identification of S‐acylated proteins/peptides via mass spectrometry. This approach enables researchers to study S‐acylation of PM proteins in plants in a systematic and straightforward way. © 2020 Wiley Periodicals LLC.Basic Protocol 1 : Preparation ofArabidopsis seedling materialsBasic Protocol 2 : Isolation and enrichment of plasma membrane proteinsSupport Protocol 1 : Determination of protein concentration using BCA assayBasic Protocol 3 : Enrichment of S‐acylated proteins by acyl‐biotin exchange methodSupport Protocol 2 : Protein precipitation by methanol/chloroform methodBasic Protocol 4 : Trypsin digestion and proteomic analysisAlternate Protocol : Pre‐resin digestion and peptide‐level enrichment -
more » « less
Abstract Histone acetyltransferases (HATs, also known as lysine acetyltransferases, KATs) catalyze acetylation of their cognate protein substrates using acetyl‐CoA (Ac‐CoA) as a cofactor and are involved in various physiological and pathological processes. Advances in mass spectrometry‐based proteomics have allowed the discovery of thousands of acetylated proteins and the specific acetylated lysine sites. However, due to the rapid dynamics and functional redundancy of HAT activities, and the limitation of using antibodies to capture acetylated lysines, it is challenging to systematically and precisely define both the substrates and sites directly acetylated by a given HAT. Here, we describe a chemoproteomic approach to identify and profile protein substrates of individual HAT enzymes on the proteomic scale. The approach involves protein engineering to enlarge the Ac‐CoA binding pocket of the HAT of interest, such that a mutant form is generated that can use functionalized acyl‐CoAs as a cofactor surrogate to bioorthogonally label its protein substrates. The acylated protein substrates can then be chemoselectively conjugated either with a fluorescent probe (for imaging detection) or with a biotin handle (for streptavidin pulldown and chemoproteomic identification). This modular chemical biology approach has been successfully implemented to identify protein substrates of p300, GCN5, and HAT1, and it is expected that this method can be applied to profile and identify the sub‐acetylomes of many other HAT enzymes. © 2022 Wiley Periodicals LLC.
Basic Protocol 1 : Labeling HAT protein substrates with azide/alkyne‐biotinAlternate Protocol : Labeling protein substrates of HATs with azide/alkyne‐TAMRA for in‐gel visualizationSupport Protocol 1 : Expression and purification of HAT mutantsSupport Protocol 2 : Synthesis of Ac‐CoA surrogatesBasic Protocol 2 : Streptavidin enrichment of biotinylated HAT substratesBasic Protocol 3 : Chemoproteomic identification of HAT substratesBasic Protocol 4 : Validation of specific HAT substrates with western blotting -
more » « less
Abstract Nanobodies (nAbs) are recombinant antigen‐binding variable domain fragments obtained from heavy‐chain‐only immunoglobulins. Among mammals, these are unique to camelids (camels, llamas, alpacas, etc.). Nanobodies are of great use in biomedical research due to their efficient folding and stability under a variety of conditions, as well as their small size. The latter characteristic is particularly important for nAbs used as immunolabeling reagents, since this can improve penetration of cell and tissue samples compared to conventional antibodies, and also reduce the gap distance between signal and target, thereby improving imaging resolution. In addition, their recombinant nature allows for unambiguous definition and permanent archiving in the form of DNA sequence, enhanced distribution in the form of sequences or plasmids, and easy and inexpensive production using well‐established bacterial expression systems, such as the IPTG induction method described here. This article will review the basic workflow and process for developing, screening, and validating novel nAbs against neuronal target proteins. The protocols described make use of the most common nAb development method, wherein an immune repertoire from an immunized llama is screened via phage display technology. Selected nAbs can then be taken through validation assays for use as immunolabels or as intrabodies in neurons. © 2020 Wiley Periodicals LLC.
This article was corrected on 26 June 2021. See the end of the full text for details.
Basic Protocol 1 : Total RNA isolation from camelid leukocytesBasic Protocol 2 : First‐strand cDNA synthesis; VHH and VHrepertoire PCRBasic Protocol 3 : Preparation of the phage display libraryBasic Protocol 4 : Panning of the phage display libraryBasic Protocol 5 : Small‐scale nAb expressionBasic Protocol 6 : Sequence analysis of selected nAb clonesBasic Protocol 7 : Nanobody validation as immunolabelsBasic Protocol 8 : Generation of nAb‐pEGFP mammalian expression constructsBasic Protocol 9 : Nanobody validation as intrabodiesSupport Protocol 1 : ELISA for llama serum testing, phage titer, and screening of selected clonesSupport Protocol 2 : Amplification of helper phage stockSupport Protocol 3 : nAb expression in amber suppressorE. coli bacterial strains -
more » « less
Abstract Transmembrane proteins are responsible for many critical cellular functions and represent one of the largest families of drug targets. However, these proteins, especially multipass transmembrane proteins, are difficult to study because they must be embedded in a lipid bilayer to maintain their native conformations. The development of the virion display (VirD) technology enables transmembrane proteins to be integrated into the viral envelope of herpes simplex virus 1 (HSV‐1). Combining high‐throughput cloning, expression, and purification techniques, VirD technology has been applied to the largest set of human transmembrane proteins, namely G‐protein‐coupled receptors, and has allowed the identification of interactions that are both specific and functional. This article describes the procedures to integrate an open reading frame for any transmembrane protein into the HSV‐1 genome and produce recombinant HSV‐1 virus to ultimately generate pure VirD virions for biological and pharmaceutical studies. © 2020 Wiley Periodicals LLC.
Basic Protocol 1 : Gateway cloning of transmembrane proteinsSupport Protocol 1 : Ethanol precipitation of bacterial artificial chromosomal DNASupport Protocol 2 : Preparation of competent cellsBasic Protocol 2 : Production of recombinant HSV‐1 virions
